Eisai: Additional Detailed Analyses from Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals

TOKYO and CAMBRIDGE, Mass., Mar 31, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that three additional detailed analyses from the Phase IIb clinical study (Study

Related Keywords

United Kingdom ,Tokyo ,Japan ,Australia ,New Zealand ,United States ,Russia ,China ,Cambridge ,Cambridgeshire ,Libby Holman ,Stefan Klotter ,Mike Hencke ,Natacha Gassenbach ,Alzheimer Network Trials Unit ,Linkedin ,Ministry Of Health ,Alzheimer Research ,Translational Research ,Twitter ,Devices Agency ,Investor Relations Department ,Nasdaq ,Drug Administration ,United Nations Sustainable Development Goals Sdgs ,Eisai Inc ,National Medical Products Administration ,Facebook ,National Institute On ,Advisory Committee ,Eisai Europe Ltd ,European Medicines Agency ,Washington University School Of Medicine ,Alzheimer Clinical Trial Consortium ,Exchange Commission ,National Institutes Of Health ,Eisai Co Ltd ,Biogen Inc ,Youtube ,Communications Department ,Public Relations Department ,Clinical Dementia Rating Sum Of Boxes ,Scale Cognitive Subscale ,Brand Name ,Prescribing Information ,Clinical Trials ,New England Journal ,Biologics License Application ,Priority Review ,Prescription Drug User Fee Act ,Medical Devices Agency ,Clinical Trial Consortium ,National Institute ,National Institutes ,Tau Nexgen ,Dominantly Inherited ,Washington University School ,Corporate Concept ,United Nations Sustainable Development Goals ,Private Securities Litigation Reform Act ,Diese Aktien ,Profi Stefan Klotter ,Eisai ,Dditional ,Etailed ,Analyses ,Rom ,Hase ,Study ,Lecanemab ,Published ,Three ,Papers ,Beer ,Eviewed ,Ournals ,